Literature DB >> 22292577

Evaluation of the pattern of human albumin utilization at a university affiliated hospital.

Azita Hajhossein Talasaz1, Zahra Jahangard-Rafsanjani, Shadi Ziaie, Fanak Fahimi.   

Abstract

BACKGROUND: Albumin is a protein colloidal solution that possesses great value in the clinic, particularly for the resuscitation of critically ill patients. It has accounted for a high percentage of the cost in our center. This study evaluates the appropriateness of albumin usage at Masih Daneshvari Hospital, Tehran, Iran.
METHODS: This study evaluated 69 patient charts. Data included patient demographics, ward of admission, primary reasons for prescribing albumin, and details of albumin use. Possible correlations between the appropriateness of albumin usage, the number of albumin vials, and mortality rate were analyzed.
RESULTS: Albumin was prescribed appropriately in 63.8% of patients. Cardiac surgery accounted for 37.3% of all indications. The most prevalent inappropriate indication of albumin was for mild hypoalbuminemia and nutritional support. There was a significant correlation between the number of used albumin vials and mortality rate. In conclusion, the albumin use in Masih Daneshvari Hospital was not completely in accordance with the accredited references.
CONCLUSION: Albumin is an expensive medication prescribed unnecessarily for many patients. Using the clinical pharmacist's prepared guideline could minimize the situations where its administration is not needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22292577     DOI: 012152/AIM.007

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  8 in total

1.  Drug utilization evaluation of albumin in a teaching hospital of Mashhad, Iran: an interventional pre-post design study.

Authors:  Farzaneh Zolfagharian; Saba Ghazanfari; Sepideh Elyasi; Paria Iraji; Mohammad Reza Saberi; Nasser Vahdati-Mashhadian; Amir Hooshang Mohammadpour
Journal:  Int J Clin Pharm       Date:  2017-05-24

2.  Clinical pharmacy services in an Iranian teaching hospital: Type, severity, resolution, and accuracy.

Authors:  Zahra Allameh; Maryam Mehrpooya; Shadi Baniasadi; Fanak Fahimi
Journal:  J Res Pharm Pract       Date:  2013-01

3.  Weakening Impact of Excessive Human Serum Albumin (eHSA) on Cisplatin and Etoposide Anticancer Effect in C57BL/6 Mice with Tumor and in Human NSCLC A549 Cells.

Authors:  Zhen Yang; Ting Zhou; Yuanchi Cheng; Mingming Li; Xianglin Tan; Feng Xu
Journal:  Front Pharmacol       Date:  2016-11-15       Impact factor: 5.810

4.  Albumin Utilization Evaluation in a Major Teaching Hospital in Iran: Recommendations for Guideline Development.

Authors:  Maryam Farasatinasab; Atefeh Amouzegar; Saeed Safari; Behrooz Ghanbari; Majid Darkahian; Sepideh Emami; Nashmin Pakdaman; Maryam Salili
Journal:  J Res Pharm Pract       Date:  2018 Jul-Sep

5.  Impact of Protocol Implementation on Rationalization of Albumin Use in a Tertiary Care Teaching Hospital in Tehran, Iran.

Authors:  Sholeh Ebrahimpour; Marzieh Nosrati; Mehdi Mohammadi; Haniyeh Kamyab; Amir Sarayani; Habibollah Mahmoodzadeh; Zahra Jahangard-Rafsanjani; Kheirollah Gholami
Journal:  J Res Pharm Pract       Date:  2018 Oct-Dec

6.  Reducing Inappropriate Utilization of Albumin: The Value of Pharmacist-led Intervention Model.

Authors:  Farzaneh Dastan; Hamidreza Jamaati; Habib Emami; Rodabeh Haghgoo; Raha Eskandari; Seyedeh Shadab Hashemifard; Fatemeh Khoddami; Zahra Mirshafiei Langari
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

7.  The Impact of Clinical Pharmacist Implemented Protocol on Albumin Utilization and Cost in an Intensive Care Unit in Egypt.

Authors:  Dina Mohamed Ibrahim; May Ahmed Shawki; Mohamed Hassan Solayman; Nagwa Ali Sabri
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

8.  Investigating the Use of Human Albumin in a Non-Teaching Hospital in Iran.

Authors:  Farzaneh Foroughinia; Shahriar Mazraie
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.